Public Comments

You are here

Comments to the FDA on Clarification of When Products Made or Derived From Tobacco Are Regulated as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding “Intended Uses”; Further Delay

Comments to the FDA on Clarification of When Products Made or Derived From Tobacco Are Regulated as Drugs, Devices, or Combination Products; Amendments to Regulations Regarding “Intended Uses”; Further Delay

Consortium Comment on FDA Draft Guidance (2016)

The Tobacco Control Legal Consortium's comment to the U.S. Food and Drug Administration (FDA) on the FDA’s draft guidance, “Procedures for Evaluating Appearance Issues and Granting Authorizations for Participation in FDA Advisory Committees.”

AttachmentSize
PDF icon Consortium-Comment-To-FDA-Nov2016.pdf259.49 KB

Comments to HUD on Instituting Smoke-Free Public Housing (2016)

Public comments submitted by the Tobacco Control Legal Consortium to HUD on their proposed smoke-free public housing rule.

Comments to FDA on Lorillard Petition for Enforcement Discretion Regarding Premarket Approval Requirements for New Tobacco Products (August 2014)

Consortium’s comments to FDA on Lorillard’s petition for enforcement discretion with respect to premarket approval requirements for new tobacco products.

Comments on Lorillard Petition for Enforcement Discretion Regarding Premarket Approval Requirements for New Tobacco Products (August 2014)

Consortium’s comments to FDA on Lorillard’s petition for enforcement discretion with respect to premarket approval requirements for new tobacco products.

Consortium's Comments to FDA on Proposed Deeming Regulation (August 2014)

Consortium's comments to the Food and Drug Administration's on the agency's proposed deeming regulation to assert jurisdiction over non-cigarette tobacco products (August 2014).

Consortium's Comments to FDA on Possible FDA Regulation of Menthol in Cigarettes (July 2014)

Consortium's comments to FDA on FDA's preliminary evaluation and data, research or other information that might informa regulatory actions the FDA might take regarding menthol in cigarettes.

Comments to FDA on Approaches to Evaluation of Modified Risk Tobacco Products (April 2014)

Comments to FDA on possible approaches for evaluating information on the risks and potential benefits of a proposed modified risk tobacco product to the health of individual tobacco users and to the population as a whole.

Comments to FDA on Experimental Study on Public Display of Lists of Harmful and Potentially Harmful Tobacco Constituents (August 2013)

Comments to FDA on the FDA's consumer research, "Experimental Study on the Public Display of Lists of Harmful and Potentially Harmful Tobacco Tobacco Constituents."

Comments to FDA on Evaluating Information on Proposed Modified Risk Tobacco Product (August 2013)

Comments to FDA on possible approaches for evaluating information on the risks and potential benefits of a proposed modified risk tobacco product to the population as a whole.

Comments to FDA on the Collection of Health Documents (June 2013)

Comments to FDA on the collection of health documents created from June 22, 2009 through December 31, 2009, pursuant to the Food, Drug and Cosmetic Act (Sec. 904), as amended by the Family Smoking PRevention and Tobacco Control Act of 2009.

Comments to FDA on Testing for Harmful Constituents in Tobacco Products and Tobacco Smoke (June 2012)

Comments to FDA on guidance for the tobacco industry on reporting harmful and potentially harmful constituents in tobacco products and tobacco smoke.

PHLP and Consortium Comments to FDA on Sale and Distribution of Cigarettes & Smokeless Tobacco (May 2011)

PHLP and Consortium comments to FDA on draft guidance regarding compliance with regulations estricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents.

Consortium's Comments to FDA on Required Warnings for Cigarette Packages and Advertisements (Jan. 2011)

Consortium's comments to FDA addressing its proposed 2010 rule regarding required warnings for cigarette packages and advertisements.

Consortium's Comments to FDA on Impact of Dissolvable Tobacco Use on Public Health (Sept. 2010)

Consortium comments to FDA on weaknesses in the regulation of dissolvable tobacco products at the state and federal level.

Comments to FTC on Information Requests to Marketers of Electronic Cigarettes (2015)

Comments on the Federal Trade Commission’s (FTC) request for comment on proposed information requests to marketers of electronic cigarettes, or electronic nicotine delivery systems (ENDS).

AttachmentSize
PDF icon Comment-to-FTC-on-ENDS-report.pdf481.37 KB

Comments to FDA on Smokeless Tobacco Product Warning Statements (2013)

Comments from twenty-four national organizations on what changes, if any, to the current statutory warnings on smokeless tobacco products would promote greater public understanding of the risks associated with the use of smokeless tobacco products.